The patent approvals extend and strengthen BiondVax’s intellectual property portfolio
Nes Ziona, Israel – October 29, 2014 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), which is developing the Universal Flu Vaccine, announced today that it received approvals from the European Union and from Japan’s patent authorities for the Company’s patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family. This is a family of patents for vaccination against influenza in humans, and specifically vaccines that confer a longlasting protection against multiple flu strains. The patent approvals in Europe and Japan extend and strengthen BiondVax’s intellectual property.
The newly-approved patent in Europe and Japan has already been approved in the US, , Hong Kong, Australia, China, Russia and Mexico. In addition, the Company is in the process for patent approval in Israel, where it may be completed soon.
Ron Babecoff, CEO of BiondVax said “We are excited on the dual patent approvalstoday: both in the EU and in Japan, which strengthen the acknowledgement for BiondVax around the world. The patent approval in Europe and Japan can set the ground and support the Company, if and as we work towards signing agreements with governments to use our unique technology.”